{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=GOG+Foundation", "query": { "sponsor": "GOG Foundation", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 221, "total_pages": 23, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=4&sponsor=GOG+Foundation&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=GOG+Foundation&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T23:04:37.706Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01225887", "title": "Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Squamous Cell Carcinoma", "Endometrial Transitional Cell Carcinoma", "Endometrial Undifferentiated Carcinoma", "Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm", "Recurrent Uterine Corpus Carcinoma" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 37, "start_date": "2011-10", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-10-09", "last_synced_at": "2026-10-04T23:04:37.706Z", "location_count": 59, "location_summary": "Burbank, California • Aurora, Colorado • Hartford, Connecticut + 40 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT01225887" }, { "nct_id": "NCT00003378", "title": "Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 45, "start_date": "1998-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-09", "last_synced_at": "2026-10-04T23:04:37.706Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003378" }, { "nct_id": "NCT03894215", "title": "RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "AGEN2034", "type": "DRUG" }, { "name": "AGEN1884", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 211, "start_date": "2019-06-01", "completion_date": "2025-03-26", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-04T23:04:37.706Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03894215" }, { "nct_id": "NCT00005029", "title": "Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "FEMALE", "summary": "Up to 120 Years · Female only" }, "enrollment_count": null, "start_date": "2000-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2018-04-12", "last_synced_at": "2026-10-04T23:04:37.706Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005029" }, { "nct_id": "NCT00003386", "title": "Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "BCG vaccine", "type": "BIOLOGICAL" }, { "name": "autologous tumor cell vaccine", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "dinitrophenyl", "type": "OTHER" }, { "name": "surgical procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "1999-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-11", "last_synced_at": "2026-10-04T23:04:37.706Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Gatos", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003386" }, { "nct_id": "NCT00060359", "title": "Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Carcinoma", "Malignant Ovarian Mixed Epithelial Tumor", "Ovarian Brenner Tumor", "Ovarian Clear Cell Cystadenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Cystadenocarcinoma", "Ovarian Serous Cystadenocarcinoma", "Primary Peritoneal Carcinoma", "Stage III Ovarian Cancer", "Stage IV Ovarian Cancer", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel Poliglumex", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 32, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-05-08", "last_synced_at": "2026-10-04T23:04:37.706Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060359" }, { "nct_id": "NCT00956670", "title": "Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphedema", "Stage IA Cervical Cancer", "Stage IA Uterine Corpus Cancer", "Stage IA Vulvar Cancer", "Stage IB Cervical Cancer", "Stage IB Uterine Corpus Cancer", "Stage IB Vulvar Cancer", "Stage II Uterine Corpus Cancer", "Stage II Vulvar Cancer", "Stage IIA Cervical Cancer", "Stage IIIA Vulvar Cancer", "Stage IIIB Vulvar Cancer", "Stage IIIC Vulvar Cancer", "Stage IVB Vulvar Cancer" ], "interventions": [ { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Study of High Risk Factors", "type": "PROCEDURE" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Therapeutic Laparoscopic Surgery", "type": "PROCEDURE" }, { "name": "Therapeutic Lymphadenectomy", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1055, "start_date": "2012-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-05-08", "last_synced_at": "2026-10-04T23:04:37.706Z", "location_count": 213, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00956670" }, { "nct_id": "NCT00003322", "title": "Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 384, "start_date": "1998-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-27", "last_synced_at": "2026-10-04T23:04:37.706Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003322" }, { "nct_id": "NCT00004037", "title": "Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "1998-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-11", "last_synced_at": "2026-10-04T23:04:37.706Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004037" }, { "nct_id": "NCT01642082", "title": "Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenocarcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Mixed Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Squamous Cell Carcinoma", "Endometrial Transitional Cell Carcinoma", "Endometrial Undifferentiated Carcinoma", "Recurrent Uterine Corpus Carcinoma" ], "interventions": [ { "name": "Dalantercept", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 28, "start_date": "2012-09", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2018-03-13", "last_synced_at": "2026-10-04T23:04:37.706Z", "location_count": 30, "location_summary": "San Francisco, California • Lewes, Delaware • Newark, Delaware + 19 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01642082" } ] }